Effects of (R)-(-)-1-(benzofuran-2-yl)-2-propylaminopentane hydrochloride [(-)-BPAP] in animal models of mood disorders

Behavioural Brain Research

Volumn 189, Issue 1, 2008, Pages 107-116

  Tsunekawa, Hiroko ^b,c   Noda, Yukihiro ^b,d   Miyazaki, Masayuki ^b   Yoneda, Fumio ^c   Nabeshima, Toshitaka ^a,b,e   Wang, Dayong ^f  

^a MEIJO UNIVERSITY   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c Research Institute   (Japan)

^d Faculty of Pharmacy   (Japan)

^e Japanese Drug Organization of Appropriate Use and Research   (Japan)

^f UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

(R) ( ) 1 (Benzofuran 2 yl) 2 propylaminopentane hydrochloride ( ) BPAP ; Dopaminergic system; Forced swimming; Imipramine; Mood disorder; Olfactory bulbectomy

Indexed keywords

1 (BENZOFURAN 2 YL) 2 PROPYLAMINOPENTANE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; BENZOFURAN DERIVATIVE; DOPAMINE RECEPTOR BLOCKING AGENT; IMIPRAMINE; SULPIRIDE; UNCLASSIFIED DRUG;

ACUTE DRUG ADMINISTRATION; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHRONIC DRUG ADMINISTRATION; CIRCADIAN RHYTHM; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG EFFICACY; FEAR; FORCED SWIMMING TEST; LEARNING; LOCOMOTION; MALE; MOOD DISORDER; MOUSE; NONHUMAN; OLFACTORY BULBECTOMY; OPEN FIELD BEHAVIOR; PRIORITY JOURNAL; SEXUAL DYSFUNCTION; SOCIAL INTERACTION;

ACOUSTIC STIMULATION; ANALYSIS OF VARIANCE; ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; BENZOFURANS; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION, PRECLINICAL; IMIPRAMINE; MALE; MICE; MOOD DISORDERS; NEURAL INHIBITION; OLFACTORY BULB; RATS; RATS, SPRAGUE-DAWLEY; SOCIAL BEHAVIOR; STARTLE REACTION;

EID: 40849085082     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbr.2007.12.016     Document Type: Article

References (49)

1. Agid Y., Ruberg M., Dubois B., and Javoy-Agid F. Biochemical substrates of mental disturbances in Parkinson's disease. Adv Neurol 40 (1984) 211-218
2. Anisman H., and Zacharko R.M. Multiple neurochemical and behavioral consequences of stressors: implications for depression. Pharmacol Ther 46 1 (1990) 119-136
3. Baxter Jr. L.R., Schwartz J.M., Phelps M.E., Mazziotta J.C., Guze B.H., Selin C.E., et al. Reduction of prefrontal cortex glucose metabolism common to three types of depression. Arch Gen Psychiatry 46 3 (1989) 243-250
4. Bertaina-Anglade V., La Rochelle C.D., and Scheller D.K. Antidepressant properties of rotigotine in experimental models of depression. Eur J Pharmacol 548 1-3 (2006) 106-114
5. Boyer P. Do anxiety and depression have a common pathophysiological mechanism?. Acta Psychiatr Scand Suppl 406 (2000) 24-29
6. Branchek T.A., and Blackburn T.P. Trace amine receptors as targets for novel therapeutics: legend, myth and fact. Curr Opin Pharmacol 3 1 (2003) 90-97
7. Broadwell R.D. Olfactory relationships of the telencephalon and diencephalon in the rabbit. I. An autoradiographic study of the efferent connections of the main and accessory olfactory bulbs. J Comp Neurol 163 3 (1975) 329-345
8. Cabib S., and Puglisi-Allegra S. Opposite responses of mesolimbic dopamine system to controllable and uncontrollable aversive experiences. J Neurosci 14 5 Pt 2 (1994) 3333-3340
9. Cabib S., and Puglisi-Allegra S. Stress, depression and the mesolimbic dopamine system. Psychopharmacology (Berl) 128 4 (1996) 331-342
10. Cabib S., Zocchi A., and Puglisi-Allegra S. A comparison of the behavioral effects of minaprine, amphetamine and stress. Psychopharmacology (Berl) 121 1 (1995) 73-80
11. Cancela L.M., Rossi S., and Molina V.A. Effect of different restraint schedules on the immobility in the forced swim test: modulation by an opiate mechanism. Brain Res Bull 26 5 (1991) 671-675
12. Deutch A.Y., Clark W.A., and Roth R.H. Prefrontal cortical dopamine depletion enhances the responsiveness of mesolimbic dopamine neurons to stress. Brain Res 521 1-2 (1990) 311-315
13. Enomoto T., Noda Y., Mouri A., Shin E.J., Wang D., Murai R., et al. Long-lasting impairment of associative learning is correlated with a dysfunction of N-methyl-d-aspartate-extracellular signaling-regulated kinase signaling in mice after withdrawal from repeated administration of phencyclidine. Mol Pharmacol 68 6 (2005) 1765-1774
14. 2-like dopamine receptor mediation of social-emotional reactivity in a mouse model of anxiety: strain and experience effects. Neuropsychopharmacology 18 3 (1998) 210-221
15. Gerlach M., Jellinger K., and Riederer P. The Possible Role of Noradrenergic Deficits in Selected Signs of Parkinson's Disease (1994), CRC Press pp. 59-71
16. Harro J., Tonissaar M., Eller M., Kask A., and Oreland L. Chronic variable stress and partial 5-HT denervation by parachloroamphetamine treatment in the rat: effects on behavior and monoamine neurochemistry. Brain Res 899 1-2 (2001) 227-239
17. Heim C., and Nemeroff C.B. The impact of early adverse experiences on brain systems involved in the pathophysiology of anxiety and affective disorders. Biol Psychiatry 46 11 (1999) 1509-1522
18. Hellweg R., Zueger M., Fink K., Hortnagl H., and Gass P. Olfactory bulbectomy in mice leads to increased BDNF levels and decreased serotonin turnover in depression-related brain areas. Neurobiol Dis 25 1 (2007) 1-7
19. Jimerson D.C. Role of dopamine mechanisms in affective disorders. Psychopharmacol: Third Generation Progress (1987) 505-511
20. Kapur S., and Mann J.J. Role of the dopaminergic system in depression. Biol Psychiatry 32 1 (1992) 1-17
21. Katz R.J. Animal model of depression: pharmacological sensitivity of a hedonic deficit. Pharmacol Biochem Behav 16 6 (1982) 965-968
22. Katz R.J., Roth K.A., and Carroll B.J. Acute and chronic stress effects on open field activity in the rat: implications for a model of depression. Neurosci Biobehav Rev 5 2 (1981) 247-251
23. Kelly J.P., Wrynn A.S., and Leonard B.E. The olfactory bulbectomized rat as a model of depression: an update. Pharmacol Ther 74 3 (1997) 299-316
24. Kessler R.C., Chiu W.T., Demler O., Merikangas K.R., and Walters E.E. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62 6 (2005) 617-627
25. King D., Zigmond M.J., and Finlay J.M. Effects of dopamine depletion in the medial prefrontal cortex on the stress-induced increase in extracellular dopamine in the nucleus accumbens core and shell. Neuroscience 77 1 (1997) 141-153
26. Knoll J. Enhancer regulation/endogenous and synthetic enhancer compounds: a neurochemical concept of the innate and acquired drives. Neurochem Res 28 8 (2003) 1275-1297
27. Knoll J., Miklya I., Knoll B., Yasusa T., Shimazu S., and Yoneda F. 1-(Benzofuran-2-yl)-2-(3,3,3-trifluoropropyl)aminopentane HCl, 3-F-BPAP, antagonizes the enhancer effect of (-)-BPAP in the shuttle box and leaves the effect of (-)-deprenyl unchanged. Life Sci 71 17 (2002) 1975-1984
28. Knoll J., Yoneda F., Knoll B., Ohde H., and Miklya I. (-)1-(Benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain. Br J Pharmacol 128 8 (1999) 1723-1732
29. Kusljic S., and van den Buuse M. Differential involvement of 5-HT projections within the amygdala in prepulse inhibition but not in psychotomimetic drug-induced hyperlocomotion. Behav Brain Res 168 1 (2006) 74-82
30. Lightowler S., Kennett G.A., Williamson I.J., Blackburn T.P., and Tulloch I.F. Anxiolytic-like effect of paroxetine in a rat social interaction test. Pharmacol Biochem Behav 49 2 (1994) 281-285
31. Mathew S.J., Coplan J.D., and Gorman J.M. Neurobiological mechanisms of social anxiety disorder. Am J Psychiatry 158 10 (2001) 1558-1567
32. Mayberg H.S., and Solomon D.H. Depression in Parkinson's disease: a biochemical and organic viewpoint. Adv Neurol 65 (1995) 49-60
33. Moreau J.L., Jenck F., Martin J.R., Mortas P., and Haefely W.E. Antidepressant treatment prevents chronic unpredictable mild stress-induced anhedonia as assessed by ventral tegmentum self-stimulation behavior in rats. Eur Neuropsychopharmacol 2 1 (1992) 43-49
34. Nestler E.J., Barrot M., DiLeone R.J., Eisch A.J., Gold S.J., and Monteggia L.M. Neurobiology of depression. Neuron 34 1 (2002) 13-25
35. Noda Y., Kamei H., Mamiya T., Furukawa H., and Nabeshima T. Repeated phencyclidine treatment induces negative symptom-like behavior in forced swimming test in mice: imbalance of prefrontal serotonergic and dopaminergic functions. Neuropsychopharmacology 23 4 (2000) 375-387
36. Pijlman F.T., Wolterink G., and van Ree J.M. Cueing unavoidable physical but not emotional stress increases long-term behavioural effects in rats. Behav Brain Res 134 1-2 (2002) 393-401
37. Price J.L., and Powell T.P. An experimental study of the origin and the course of the centrifugal fibres to the olfactory bulb in the rat. J Anat 107 Pt 2 (1970) 215-237
38. Puglisi-Allegra S., Kempf E., and Cabib S. Role of genotype in the adaptation of the brain dopamine system to stress. Neurosci Biobehav Rev 14 4 (1990) 523-528
39. Redmond A.M., Kelly J.P., and Leonard B.E. Behavioural and neurochemical effects of dizocilpine in the olfactory bulbectomized rat model of depression. Pharmacol Biochem Behav 58 2 (1997) 355-359
40. Rossetti Z.L., Lai M., Hmaidan Y., and Gessa G.L. Depletion of mesolimbic dopamine during behavioral despair: partial reversal by chronic imipramine. Eur J Pharmacol 242 3 (1993) 313-315
41. Rutkoski N.J., Lerant A.A., Nolte C.M., Westberry J., and Levenson C.W. Regulation of neuropeptide Y in the rat amygdala following unilateral olfactory bulbectomy. Brain Res 951 1 (2002) 69-76
42. Shimazu S., Takahata K., Katsuki H., Tsunekawa H., Tanigawa A., Yoneda F., et al. (-)-1-(Benzofuran-2-yl)-2-propylaminopentane enhances locomotor activity in rats due to its ability to induce dopamine release. Eur J Pharmacol 421 3 (2001) 181-189
43. Shimazu S., Tsunekawa H., Yoneda F., Katsuki H., Akaike A., and Janowsky A. Transporter-mediated actions of R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane. Eur J Pharmacol 482 1-3 (2003) 9-16
44. Taoka H., Hamamura T., Endo S., Miki M., Lee Y., Miyata S., et al. G(olf) protein levels in rat striatum are increased by chronic antidepressant administration and decreased by olfactory bulbectomy. Life Sci 79 5 (2006) 462-468
45. 1-receptor agonists and neuroactive steroids in mice submitted to the forced swimming test. J Pharmacol Exp Ther 298 3 (2001) 1269-1279
46. Wang D., Noda Y., Tsunekawa H., Zhou Y., Miyazaki M., Senzaki K., et al. Behavioural and neurochemical features of olfactory bulbectomized rats resembling depression with comorbid anxiety. Behav Brain Res 178 2 (2007) 262-273
47. Willner P. Animal models as simulations of depression. Trends Pharmacol Sci 12 4 (1991) 131-136
48. Yirmiya R. Endotoxin produces a depressive-like episode in rats. Brain Res 711 1-2 (1996) 163-174
49. Yoneda F., Moto T., Sakae M., Ohde H., Knoll B., Miklya I., et al. Structure-activity studies leading to (-)1-(benzofuran-2-yl)-2-propylaminopentane, ((-)BPAP), a highly potent, selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain. Bioorg Med Chem 9 5 (2001) 1197-1212